A staggering number of families have made claims against the drug manufacturing company GlaxoSmithKline. These claims are centered around GlaxoSmithKline’s drug Zofran (the generic form of which is named ondansetron and is commonly used to prevent nausea, vomiting and other sicknesses in cancer patients during various cancer surgeries, chemotherapy and radiation therapy) and that Zofran factored into negative effects as a result of being prescribed and consuming the drug while pregnant, particularly in terms of various types of birth defects.
Zofran is a drug that frequently can be prescribed and used in attempts to cure morning sickness in pregnant females. Many of the women are prescribed Zofran during their first trimester (due to the large amount of nausea and overall morning sickness experienced during that specific period of their pregnancy). Furthermore, research has found that during the first trimester of the pregnancy the fetus is its most vulnerable. Thus the fetus can be negatively affected by outside elements that factor into proper human development, such as the Zofran drug taken by their pregnant mothers during pregnancy.
The FDA has recognized Zofran a Category B pregnancy medication. This recognition has been given to Zofran because a properly controlled testing of the drug’s safety is unavailable to be done on pregnant women. Although, researchers have continued to examine the effects of Zofran by observing infants, whose mothers took Zofran, after their birth. Many researchers have found an increase in negative effects among those infants, when compared to infants whose mothers did not take Zofran during pregnancy. The birth defects of Zofran include: